Nasus Pharma
Nasus Pharma is a late-stage specialty pharmaceutical company that develops powder-based intranasal products aimed at addressing acute medical conditions and public health threats. Their mission is to offer better protection to patients during severe, life-threatening conditions through effective, user-friendly, safe, and immediately active intranasal products. They focus on rapid drug delivery, ease of use, non-invasiveness, and safety, with a portfolio that includes intranasal Naloxone and Epinephrine products, among others.
Industries
Nr. of Employees
small (1-50)
Patents
Products
Intranasal naloxone — powder nasal single‑dose product (4 mg)
A powder‑based, single‑use nasal formulation of naloxone delivered via a unidose nasal powder device; clinical data reported showing significantly faster early systemic absorption compared to a solution nasal spray.
Intranasal epinephrine — powder nasal spray (developmental)
A powder intranasal epinephrine formulation developed for emergency treatment of anaphylaxis; clinical pilot and Phase 2 data reported showing faster time to therapeutic blood levels and higher early exposure under nasal congestion models.
Intranasal naloxone — powder nasal single‑dose product (4 mg)
A powder‑based, single‑use nasal formulation of naloxone delivered via a unidose nasal powder device; clinical data reported showing significantly faster early systemic absorption compared to a solution nasal spray.
Intranasal epinephrine — powder nasal spray (developmental)
A powder intranasal epinephrine formulation developed for emergency treatment of anaphylaxis; clinical pilot and Phase 2 data reported showing faster time to therapeutic blood levels and higher early exposure under nasal congestion models.
Services
Design and execution of human clinical programs for intranasal powder drug‑device combinations, including pilot, Phase 2 and pivotal bioavailability/bioequivalence trials.
R&D services covering formulation design, particle engineering and preclinical proof‑of‑concept for powder‑based nasal therapeutics.
Design and execution of human clinical programs for intranasal powder drug‑device combinations, including pilot, Phase 2 and pivotal bioavailability/bioequivalence trials.
R&D services covering formulation design, particle engineering and preclinical proof‑of‑concept for powder‑based nasal therapeutics.
Expertise Areas
- Intranasal drug delivery
- Powder formulation and particle engineering
- Clinical trial management (bioequivalence, Phase 2, pivotal)
- Pharmacokinetics and bioavailability analysis
Key Technologies
- Intranasal dry powder delivery
- Microsphere API formulation
- Particle size and morphology control
- Inhalation‑approved carrier systems (lactose‑based carriers)